ZA201504762B - Nanoparticle compositions of albumin and paclitaxel - Google Patents

Nanoparticle compositions of albumin and paclitaxel

Info

Publication number
ZA201504762B
ZA201504762B ZA2015/04762A ZA201504762A ZA201504762B ZA 201504762 B ZA201504762 B ZA 201504762B ZA 2015/04762 A ZA2015/04762 A ZA 2015/04762A ZA 201504762 A ZA201504762 A ZA 201504762A ZA 201504762 B ZA201504762 B ZA 201504762B
Authority
ZA
South Africa
Prior art keywords
paclitaxel
albumin
nanoparticle compositions
nanoparticle
compositions
Prior art date
Application number
ZA2015/04762A
Other languages
English (en)
Inventor
P Desai Neil
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of ZA201504762B publication Critical patent/ZA201504762B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2015/04762A 2012-12-28 2015-07-02 Nanoparticle compositions of albumin and paclitaxel ZA201504762B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747123P 2012-12-28 2012-12-28
US13/794,705 US20140186447A1 (en) 2012-12-28 2013-03-11 Nanoparticle compositions of albumin and paclitaxel
PCT/US2013/076630 WO2014105644A1 (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Publications (1)

Publication Number Publication Date
ZA201504762B true ZA201504762B (en) 2016-10-26

Family

ID=51017455

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/04762A ZA201504762B (en) 2012-12-28 2015-07-02 Nanoparticle compositions of albumin and paclitaxel

Country Status (19)

Country Link
US (2) US20140186447A1 (enExample)
EP (1) EP2938340A4 (enExample)
JP (2) JP2016504362A (enExample)
KR (1) KR20150100903A (enExample)
CN (1) CN105007912A (enExample)
AU (1) AU2013370955B2 (enExample)
BR (1) BR112015015319A2 (enExample)
CA (1) CA2896288A1 (enExample)
CR (1) CR20150386A (enExample)
HK (1) HK1216611A1 (enExample)
IL (1) IL239593A0 (enExample)
MX (1) MX2015008361A (enExample)
NI (1) NI201500090A (enExample)
NZ (1) NZ630912A (enExample)
PH (1) PH12015501486B1 (enExample)
RU (1) RU2663687C2 (enExample)
SG (1) SG11201505111TA (enExample)
WO (1) WO2014105644A1 (enExample)
ZA (1) ZA201504762B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PL1931321T3 (pl) 2005-08-31 2019-08-30 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
WO2008150532A1 (en) * 2007-06-01 2008-12-11 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
MX378130B (es) 2009-04-15 2025-03-10 Abraxis Bioscience Llc Métodos y composiciones de nanopartículas sin priones.
PT2552438T (pt) 2010-03-26 2016-07-07 Abraxis Bioscience Llc Métodos de tratamento de carcinoma hepatocelular
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
LT2707030T (lt) 2011-05-09 2020-07-10 Mayo Foundation For Medical Education And Research Vėžio gydymas
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US10744110B2 (en) 2013-03-12 2020-08-18 Abraxis Bioscience, Llc Methods of treating lung cancer
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
CN112107558A (zh) 2013-05-30 2020-12-22 库拉迪格姆公司 药物组合物、制备及其用途
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
AU2015277494A1 (en) 2014-06-16 2017-01-12 Mayo Foundation For Medical Education And Research Treating myelomas
CN104224750A (zh) * 2014-09-17 2014-12-24 四川大学 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
DK3236934T3 (da) 2014-11-25 2024-08-19 Curadigm Sas Farmaceutisk sammensætning, fremstilling og anvendelser deraf
EP3229843B1 (en) * 2014-11-25 2020-01-01 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
US11304902B2 (en) 2014-11-25 2022-04-19 Curadigm Sas Pharmaceutical compositions, preparation and uses thereof
LT3229776T (lt) 2014-11-25 2023-08-25 Curadigm Sas Farmacinė kompozicija, kurioje derinamos mažiausiai dvi skirtingos nanodalelės ir farmacinis mišinys, jos paruošimas ir vartojimas
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN118286421A (zh) 2015-05-28 2024-07-05 纳米生物技术公司 用作治疗性疫苗的纳米粒子
KR102606071B1 (ko) 2015-06-29 2023-11-27 아브락시스 바이오사이언스, 엘엘씨 상피양 세포 종양을 치료하는 방법
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
KR20220151022A (ko) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체-pd-l1 결합제 조성물
EP3509643A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
CN106420665B (zh) * 2016-10-28 2019-04-16 浙江省林业科学研究院 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法
WO2019070850A1 (en) * 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
KR102837015B1 (ko) 2018-03-20 2025-07-23 아브락시스 바이오사이언스, 엘엘씨 mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법
WO2021050799A1 (en) * 2019-09-13 2021-03-18 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
CA3158764A1 (en) * 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN114945358A (zh) * 2019-11-11 2022-08-26 阿布拉科斯生物科学有限公司 用于纳米颗粒组合物的生物标记
WO2021158937A1 (en) * 2020-02-05 2021-08-12 The Johns Hopkins University Bortezomib-loaded nanoparticles
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
EP4375659B1 (en) * 2022-11-28 2025-03-26 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
IL141155A0 (en) * 1998-07-30 2002-02-10 Human Rt Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
MX340670B (es) * 2009-08-25 2016-07-20 Abraxis Bioscience Llc * Terapia combinada con composiciones de nanoparticulas de taxano e inhibidores de hedgehog.
PT2552438T (pt) * 2010-03-26 2016-07-07 Abraxis Bioscience Llc Métodos de tratamento de carcinoma hepatocelular
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂

Also Published As

Publication number Publication date
CA2896288A1 (en) 2014-07-03
BR112015015319A2 (pt) 2017-07-11
AU2013370955A1 (en) 2015-07-16
KR20150100903A (ko) 2015-09-02
PH12015501486B1 (en) 2020-12-16
US20190192477A1 (en) 2019-06-27
NZ630912A (en) 2017-05-26
IL239593A0 (en) 2015-08-31
EP2938340A1 (en) 2015-11-04
PH12015501486A1 (en) 2015-09-21
CN105007912A (zh) 2015-10-28
MX2015008361A (es) 2016-03-11
WO2014105644A1 (en) 2014-07-03
RU2015131141A (ru) 2017-02-03
AU2013370955B2 (en) 2018-12-06
RU2663687C2 (ru) 2018-08-08
NI201500090A (es) 2015-12-22
HK1216611A1 (zh) 2016-11-25
CR20150386A (es) 2015-10-07
SG11201505111TA (en) 2015-07-30
EP2938340A4 (en) 2016-08-03
JP2018087241A (ja) 2018-06-07
JP2016504362A (ja) 2016-02-12
US20140186447A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
ZA201504762B (en) Nanoparticle compositions of albumin and paclitaxel
IL274971B2 (en) Silver nanoplate compositions and methods
IL272313A (en) Intravascular delivery of nanoparticle preparations and their uses
EP2814496A4 (en) NANOPARTICLES FOR MITOCHONDRIAL TRANSPORT OF ACTIVE SUBSTANCES
IL237156B (en) Microcapsule preparation and methods
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL269024A (en) The trains containing PEG and ASCORBATE
IL252566A0 (en) Pharmacy preparations and methods
GB201215289D0 (en) Nanoparticle formulation
CY2200004T2 (el) Σκευασματα δαπτομυκινης και χρησεις αυτων
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB2504390B (en) Nutraceutical and pharmaceutical composition
PT2790739T (pt) Nanopartículas e utilizações das mesmas
IL235167A0 (en) Lipid-peptide bis-polymer conjugates and their nanoparticles
IL235154A0 (en) Preparations containing substances to reduce uric acid and anti-inflammatory substances and their uses
IL238059A0 (en) History of pyrrolidine, and pharmaceutical preparations containing them
IL233961B (en) The composition of a phytogenic supplement and methods of its use
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2861586A4 (en) FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
EP2809294A4 (en) WELD-INHIBITABLE EMULSION COMPOSITIONS AND METHOD FOR PRODUCING WELD-INHIBITING MULSION COMPOSITIONS
SMT201700322T1 (it) Composizione dermoprotettiva e dermoequilibrante
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same